[Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].
Abstract
Pulmonary chronic graft-versus-host disease (cGVHD) is a clinically significant complication after allogeneic hematopoietic stem cell transplantation, severely affecting the quality of life and survival rate of hematopoietic stem cell transplantation recipients. Bronchiolitis obliterans syndrome and interstitial lung diseases are the two main clinical entities. However, the insidious onset, diagnostic challenges, and limited therapeutic options of pulmonary cGVHD result in suboptimal clinical management and poor prognosis. Based on the latest developments in pulmonary cGVHD research and increasing evidence-based medicine data, this consensus was developed collaboratively by multidisciplinary experts domestically, providing recommendations for the early recognition, diagnosis, treatment, and management of pulmonary cGVHD, aiming to establish a standardized diagnostic and therapeutic workflow for pulmonary cGVHD applicable to clinical practice in China, to better guide clinical practice and improve patients' quality of life and survival rate.
Related
- A multidisciplinary consensus report on approach to adult influenza in primary care: Diagnosis, treatment, prevention of complications and vaccination
- Chinese expert consensus on the treatment of immune‑mediated inflammatory diseases with Janus kinase inhibitors.
- How artificial intelligence could improve the diagnosis and management of chronic obstructive pulmonary disease: a perspective from GOLD
- Primary pulmonary NUT carcinoma: pathological features, clinical diagnosis, treatment, and prognosis — An extended review
- Artificial intelligence-assisted bronchoscopy for the diagnosis and treatment of pulmonary diseases: Advances and clinical practice
BibTeX
@article{chinesesocietyofhematology2026chinese,
title = {{[Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].}},
author = {Chinese Society of Hematology, Chinese Medical Association and Chinese College of Chest Physicians, Chinese Medical Doctor Association and Leukemia Committee, Chinese Society of Clinical Oncology and Immunodeficiency Committee, Guangdong Provincial Association of Basic Medicine and Guangdong Respiratory and Health Association and Committee of Hematological Immunology Diagnosis and Treatment, Guangdong Medical Education Association},
journal = {Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi},
year = {2026},
month = aug,
doi = {10.3760/cma.j.cn121090-20260520-00254},
url = {https://europepmc.org/article/MED/42851173},
note = {CC BY},
}
RIS
TY - JOUR
TI - [Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].
AU - Chinese Society of Hematology, Chinese Medical Association
AU - Chinese College of Chest Physicians, Chinese Medical Doctor Association
AU - Leukemia Committee, Chinese Society of Clinical Oncology
AU - Immunodeficiency Committee, Guangdong Provincial Association of Basic Medicine
AU - Guangdong Respiratory and Health Association
AU - Committee of Hematological Immunology Diagnosis and Treatment, Guangdong Medical Education Association
PY - 2026
DA - 2026/08/01
JO - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
DO - 10.3760/cma.j.cn121090-20260520-00254
UR - https://europepmc.org/article/MED/42851173
AB - Pulmonary chronic graft-versus-host disease (cGVHD) is a clinically significant complication after allogeneic hematopoietic stem cell transplantation, severely affecting the quality of life and survival rate of hematopoietic stem cell transplantation recipients. Bronchiolitis obliterans syndrome and interstitial lung diseases are the two main clinical entities. However, the insidious onset, diagnostic challenges, and limited therapeutic options of pulmonary cGVHD result in suboptimal clinical management and poor prognosis. Based on the latest developments in pulmonary cGVHD research and increasing evidence-based medicine data, this consensus was developed collaboratively by multidisciplinary experts domestically, providing recommendations for the early recognition, diagnosis, treatment, and management of pulmonary cGVHD, aiming to establish a standardized diagnostic and therapeutic workflow for pulmonary cGVHD applicable to clinical practice in China, to better guide clinical practice and improve patients' quality of life and survival rate.
SN - 0253-2727
SN - 2707-9740
ER -